登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《JKMS，2月14日，Case of the Index Patient Who Caused Tertiary Transmission of Coronavirus Disease 2019 in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-19 》

  • 来源专题：COVID-19科研动态监测
  • 编译者： dingxq
  • 发布时间：2020-02-16

  • Case of the Index Patient Who Caused Tertiary Transmission of Coronavirus Disease 2019 in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-19 Pneumonia Monitored by Quantitative RT-PCR

    Jaegyun Lim, Seunghyun Jeon, Hyun-Young Shin, Moon Jung Kim, Yu Min Seong, Wang Jun Lee, Kang-Won Choe, Yu Min Kang, Baeckseung Lee, and Sang-Joon Park

    DOI：https://doi.org/10.3346/jkms.2020.35.e79

    Since mid-December of 2019, coronavirus disease 2019 (COVID-19) has been spreading from Wuhan, China. The confirmed COVID-19 patients in South Korea are those who came from or visited China. As secondary transmissions have occurred and the speed of transmission is accelerating, there are rising concerns about community infections. The 54-year old male is the third patient diagnosed with COVID-19 in Korea. He is a worker for a clothing business and had mild respiratory symptoms and intermittent fever in the beginning of hospitalization, and pneumonia symptoms on chest computerized tomography scan on day 6 of admission. This patient caused one case of secondary transmission and three cases of tertiary transmission. Hereby, we report the clinical findings of the index patient who was the first to cause tertiary transmission outside China. Interestingly, after lopinavir/ritonavir (Kaletra, AbbVie) was administered, β-coronavirus viral loads significantly decreased and no or little coronavirus titers were observed.

  • 原文来源：https://jkms.org/DOIx.php?id=10.3346/jkms.2020.35.e79
5浏览量
原文链接
相关报告

  • 《LANCET，5月8日，Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial》
    • 来源专题：COVID-19科研动态监测
    • 编译者：xuwenwhlib
    • 发布时间：2020-05-09
    • Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial Prof Ivan Fan-Ngai Hung, MD Kwok-Cheung Lung, FRCP Eugene Yuk-Keung Tso, FRCP Raymond Liu, FRCP Tom Wai-Hin Chung, MRCP Man-Yee Chu, MRCP et al. Show all authors Published:May 08, 2020DOI:https://doi.org/10.1016/S0140-6736(20)31042-4 Background Effective antiviral therapy is important for tackling the coronavirus disease 2019 (COVID-19) pandemic. We assessed the efficacy and safety of combined interferon beta-1b, lopinavir–ritonavir, and ribavirin for treating patients with COVID-19. Methods This was a multicentre, prospective, open-label, randomised, phase 2 trial in adults with COVID-19 who were admitted to six hospitals in Hong Kong. Patients were randomly assigned (2:1) to a 14-day combination of lopinavir 400 mg and ritonavir 100 mg every 12 h, ribavirin 400 mg every 12 h, and three doses of 8 million international units of interferon beta-1b on alternate days (combination group) or to 14 days of lopinavir 400 mg and ritonavir 100 mg every 12 h (control group). The primary endpoint was the time to providing a nasopharyngeal swab negative for severe acute respiratory syndrome coronavirus 2 RT-PCR, and was done in the intention-to-treat population. The study is registered with ClinicalTrials.gov, NCT04276688. Findings Between Feb 10 and March 20, 2020, 127 patients were recruited; 86 were randomly assigned to the combination group and 41 were assigned to the control group. The median number of days from symptom onset to start of study treatment was 5 days (IQR 3–7). The combination group had a significantly shorter median time from start of study treatment to negative nasopharyngeal swab (7 days [IQR 5–11]) than the control group (12 days [8–15]; hazard ratio 4·37 [95% CI 1·86–10·24], p=0·0010). Adverse events included self-limited nausea and diarrhoea with no difference between the two groups. One patient in the control group discontinued lopinavir–ritonavir because of biochemical hepatitis. No patients died during the study.
    14浏览量
    原文链接

  • 《2月14日_在韩国引起2019冠状病毒疾病三代传播的索引患者病例：通过定量RT-PCR监测洛匹那韦/利托那韦在COVID-19肺炎治疗中的应用》
    • 来源专题：COVID-19科研动态监测
    • 编译者：xuwenwhlib
    • 发布时间：2020-02-17
    • 信息名称：在韩国引起2019冠状病毒疾病三代传播的索引患者病例：通过定量RT-PCR监测洛匹那韦/利托那韦在COVID-19肺炎治疗中的应用 1.时间：2020年2月14日 2.机构或团队：韩国明知医院 3.事件概要： 韩国明知医院的研究人员在Journal of Korean Medical Science在线发表题目为“Case of the Index Patient Who Caused Tertiary Transmission of Coronavirus Disease 2019 in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-19 Pneumonia Monitored by Quantitative RT-PCR”的论文。报告了在韩国引起2019冠状病毒疾病三代传播的索引患者病例。 在韩国确认的COVID-19患者是来自或访问中国的患者。随着二次传播的发生和传播速度的加快，人们越来越担心社区感染。这位54岁的男性是韩国第三位确诊为COVID-19的患者。他是一家服装公司的工人，入院初期有轻度呼吸道症状和间歇性发热，入院第6天时胸部CT扫描显示肺炎症状。该患者引起一例二次传播和三例三次传播。据此，研究人员报告了第一例在中国境外引起第三次传播的指标患者的临床表现。研究发现，服用洛匹那韦/利托那韦（Kaletra，AbbVie）后，β-冠状病毒的病毒载量显着降低，没有或很少观察到冠状病毒滴度。 4.附件： 原文链接：https://jkms.org/DOIx.php?id=10.3346/jkms.2020.35.e79
    24浏览量
    原文链接